Short-term ADT and Dose-escalated IMRT in Patients With Intermediate-risk Prostate Cancer: Benefit or Caution? Post CM, Kahn JM, Turina CB, Beer TM, et al. Am J Clin Oncol 2022;45:190-195.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Post CM, Kahn JM, Turina CB, Beer TM, et al. Short-term ADT and Dose-escalated IMRT in Patients With Intermediate-risk Prostate Cancer: Benefit or Caution? Am J Clin Oncol 2022;45:190-195.
PMID: 35446278